Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 4/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | CTSA | P10619 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | AKT2 | P31751 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | TSPO | P30536 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4492009 | 0.88 | CRHR1 (0.36) | CRHR1 | |
| SCHEMBL4498283 | 0.88 | CRHR1 (0.54) | CRHR1TLR8 | |
| SCHEMBL4494321 | 0.87 | CRHR1 (0.44) | CRHR1KDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL4489221 | 0.82 | CRHR1 (0.37) | CRHR1 | |
| SCHEMBL4482995 | 0.82 | CRHR1 (0.42) | CRHR1KDM4EALDH1A1MAPT | |
| SCHEMBL4500640 | 0.81 | CRHR1 (0.47) | CRHR1KDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL4483814 | 0.81 | CRHR1 (0.45) | CRHR1 | |
| SCHEMBL4494259 | 0.80 | CRHR1 (0.44) | CRHR1 | |
| SCHEMBL4487108 | 0.78 | CRHR1 (0.34) | CRHR1 | |
| SCHEMBL4499176 | 0.72 | CRHR1 (0.46) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281120-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ONO PHARMACEUTICAL CO., LTD (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1961745-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281120-A1 | BICYCLIC HETEROCYCLIC COMPOUND | CRHR1, NR3C1, CNR1 | CRHR1 1/4885HSP90AB1 2683/4885CTSA 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.